UK Approves Trials Testing DMT as Depression Treatment

The United Kingdom has approved trials by London-based Small Pharma for assessing the safety, and later efficacy, of N,N-dimethyltryptamine – or DMT – for depression, according to a Pharm Exec report. It is the world’s first clinical trial for studying DMT as a depression treatment.

Small Pharma CEO Peter Rand explained that DMT “delivers a psychedelic experience in 20 minutes” and the company hopes it can offer shorter therapy sessions than other psychedelics which would benefit patients in terms of cost effectiveness and convenience.

“By adopting responsible evidence-based research and development into psychedelic medicine, we hope to help rebrand these once stigmatized compounds as highly effective medical therapies, which can be integrated into current healthcare systems and made accessible to the millions of people suffering from depression.” – Rand to Pham Exec

Read More

Latest posts